Novartis AG, headquartered in Basel, Switzerland, is a leading research-driven healthcare group operating in 155 countries and regions worldwide, with approximately 108,000 employees. As a significant participant in the global pharmaceutical industry, Novartis focuses on innovative drug development and achieved revenues of approximately $54 billion in fiscal year 2025, ranking among the top 100 of the Fortune Global 500.
Core Business
Novartis centers its core business on innovative drug development, specializing in the prescription pharmaceuticals sector across key therapeutic areas including oncology, immunology, cardiovascular and metabolic diseases, and gene and cell therapies. In oncology, the group offers multiple targeted therapies and immunotherapy drugs, maintaining a global leadership position in CAR-T cell therapy, with its cell therapy products generating $1.5 billion in sales in fiscal year 2025, representing year-over-year growth of 35.2%. In immunology, Cosentyx serves as a core product for autoimmune disease treatment, achieving $4.5 billion in sales in fiscal year 2025 with growth of 8.5%. In the cardiovascular and metabolic field, Entresto continues its strong growth trajectory as a key heart failure treatment, reaching $3.5 billion in sales with growth of 12.5%. Additionally, Novartis continues to invest in cutting-edge areas such as gene and cell therapy, building an advanced therapeutic product pipeline. Innovative medicines account for 80% of the group's total revenue, fully reflecting Novartis's strategy of innovation-driven development.
Global Presence
Novartis's business network spans 155 countries and regions globally, with operational scale at the forefront of the global pharmaceutical industry. The group operates 30 global manufacturing sites and 15 R&D centers, with over 22,000 research personnel representing 20% of the total workforce. Regarding regional distribution, the U.S. market, as the largest single market, contributes 45% of revenues, Europe accounts for 25%, the Asia-Pacific region contributes 20%, and other emerging markets account for 10%. The North American market covers the United States and Canada, the European market spans over 40 countries, and the Asia-Pacific market encompasses more than 25 countries including major markets such as China, Japan, and Australia. China, as an important Asia-Pacific market, generated approximately $3 billion in revenue in fiscal year 2025. The group has established cGMP-compliant manufacturing facilities in major global pharmaceutical markets, possessing scalable production capabilities for both biologics and small molecule drugs, while ensuring efficient supply chain operations through a global logistics center network.
Key Strengths
Novartis's core competitiveness lies in its exceptional R&D capabilities and comprehensive quality systems. The group invests over $10.5 billion annually in R&D, representing 19.4% of revenue, with more than 200 projects in development and over 10,000 valid patents, achieving over 10 new drug approvals per year on average. Regarding quality systems, Novartis adheres to the world's most stringent quality standards, with products receiving full certification from major regulatory authorities globally, maintaining industry benchmark records in product safety. The operational model combining global reach with localized production, supported by advanced digital manufacturing capabilities and a robust supply chain network, positions Novartis as a significant competitive force in the global pharmaceutical market, with a brand heat score of 900.
